Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Generic Makers Scrambling to Respond to MHLW Request to Lift Shipment Restrictions, Wholesalers Fret Further Confusion
Pharma companies are scurrying to respond to the health ministry’s recent request to lift shipment restrictions for a slew of generic medicines to resolve supply shortages on the market. While manufacturers scratch their heads to predict demand after such lifting,…
To read the full story
Related Article
- FPMAJ Investigating Supply Status for 60% of All Drugs, Tally Due Out by Year-End
September 14, 2022
- Shipment Curbs Remain for Over 40% of Drugs Despite Sufficient Supply Volumes: FPMAJ Survey
June 24, 2022
- Shipment Curbs Lifted for Only 49 Products by End of 2021 after MHLW Request: FPMAJ Survey
March 25, 2022
- MHLW Publishes Brand-by-Brand Supply Status for 130 APIs Subject to Its Restriction Lifting Request
March 9, 2022
- MHLW Sets Volume Thresholds for Drug Orders to Resolve Generic Shortages
January 28, 2022
- MHLW Calls for Lifting of Shipment Restrictions for 130 Generic API/Specifications after Survey Finds YOY Rise in Supplies
December 14, 2021
BUSINESS
- China First to Approve Takeda’s Oveporexton for Narcolepsy
July 24, 2026
- FRONTEO Expects First US User of KIBIT AI Engine This Year: CEO
July 24, 2026
- Torii to Transfer Locoid MA in Japan to Cheplapharm
July 24, 2026
- Japan Vaccine Market Seen Flat in FY2026; Efluelda Delay Clouds Outlook
July 24, 2026
- Nipro Recalls Febuxostat after Finding Expired API Use at Another Plant
July 23, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…